Vimarsana
Biggest News Aggregation in the World

Page 11 - Knowledge City News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Knowledge City. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Knowledge City Today - Breaking & Trending Today

Hyderabad: Suraksha Day rally held, Check out list of events here - Vimarsana News

Hyderabad: Suraksha Day rally held, Check out list of events here

The Tri-Commissionarates of Hyderabad City Police, Cyberabad Metropolitan Police, and Warangal Police organized a rally called Suraksha Day

Source: siasat.com
Egypt aims to enhance contribution of IT sector to GDP: Talaat - Vimarsana News

Egypt aims to enhance contribution of IT sector to GDP: Talaat

Amr Talaat, Minister of Communications and Information Technology, affirmed

Source: zawya.com
'Tell Yogi...', KTR to UP banker working in 'no-nonsense' Hyderabad - Vimarsana News

'Tell Yogi...', KTR to UP banker working in 'no-nonsense' Hyderabad

Asserting Hyderabad as a no-nonsense city, Telangana IT minister KT Rama Rao said that the state government is very tough.

Source: siasat.com
Singapore's PM Lee meets Guangdong official Huang Kunming on third day of China visit - Vimarsana News

Singapore's PM Lee meets Guangdong official Huang Kunming on third day of China visit

Prime Minister Lee Hsien Loong had earlier visited the China-Singapore Guangzhou Knowledge City - an example of the partnership between the two countries.

WestVac BioPharma Co., Ltd.: Significant Progress Made on the Trivalent Recombinant Protein COVID-19 Vaccine against Subvariants including XBB.1.5 and BA.5 by WestVac Biopharma - Vimarsana News

WestVac BioPharma Co., Ltd.: Significant Progress Made on the Trivalent Recombinant Protein COVID-19 Vaccine against Subvariants including XBB.1.5 and BA.5 by WestVac Biopharma

CHENGDU, China, Feb. 20, 2023 /PRNewswire/ -- Recently, with the support of the National Key R&D Program of China, following the clinical trial approval for Recombinant Variant COVID-19 Vaccine